Odds ratio for disease manifestation in children in Sweden among serotypes included or not included in the conjugated vaccines (7-, 10- or 13-valent vaccines)
| Serotype group | Patients n | Mean age years | Pneumonia | Meningitis | Septicaemia | Underlying disease | ICU >24 h | Mortality | ||||||
| n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | n (%) | Crude OR (95% CI) | |||
| 7-valent vaccine | 101 | 3 | 33 (33) | 0.21 (0.1–0.43) | 36 (36) | 3.02 (1.28–7.13)# | 17 (17) | 1.88 (0.61–6.94) | 27 (27) | 2.74 (1.05–7.14)# | 30 (31) | 3.94 (1.37–13.98) | 2 (2) | ∞ (0.09– ∞) |
| 1, 5, 7F (10-valent) | 51 | 6 | 36 (71) | 1 (Ref) | 8 (16) | 1 (Ref) | 5 (10) | 1 (Ref) | 6 (12) | 1 (Ref) | 5 (10) | 1 (Ref) | 0 (0) | 1 (Ref) |
| 7-valent vaccine | 101 | 3 | 33 (33) | 0.88 (0.35–2.19) | 36 (36) | 1.00 (0.40–2.49) | 17 (17) | 0.65 (0.23–1.86) | 27 (27) | 1.16 (0.42–3.20) | 30 (31) | 1.76 (0.57–6.56) | 2 (2) | 0.49 (0.02–29.78) |
| 3, 6A, 19A (13-valent) | 25 | 2 | 9 (36) | 1 (Ref) | 9 (36) | 1 (Ref) | 6 (24) | 1 (Ref) | 6 (24) | 1 (Ref) | 5 (20) | 1 (Ref) | 1 (4) | 1 (Ref) |
| 7-valent vaccine | 101 | 3 | 33 (33) | 3.18 (0.66–30.62) | 36 (36) | 0.64 (0.22–1.92) | 17 (17) | 0.41 (0.11–1.74) | 27 (27) | 0.19 (0.05–0.66) | 30 (31) | 0.88 (0.25–3.59) | 2 (2) | 0.29 (0.01–17.87) |
| Non-13-valent vaccine | 15 | 4 | 2 (13) | 1 (Ref) | 7 (47) | 1 (Ref) | 5 (33) | 1 (Ref) | 10 (67) | 1 (Ref) | 5 (33) | 1 (Ref) | 1 (7) | 1 (Ref) |
| 1, 5, 7F (10-valent) | 51 | 6 | 36 (71) | 14.90 (2.86–151.8) | 8 (16) | 0.21 (0.06–0.75)# | 5 (10) | 0.22 (0.04–1.17) | 6 (12) | 0.07 (0.01–0.31) | 5 (10) | 0.23 (0.04–1.20) | 0 (0) | 0.00 (0.00–11.47) |
| Non-13-valent vaccine | 15 | 4 | 2 (13) | 1 (Ref) | 7 (47) | 1 (Ref) | 5 (33) | 1 (Ref) | 10 (67) | 1 (Ref) | 5 (33) | 1 (Ref) | 1 (7) | 1 (Ref) |
| 3, 6A, 19A (13-valent) | 25 | 2 | 9 (36) | 3.55 (0.58–39.45) | 9 (36) | 0.64 (0.17–2.36) | 6 (24) | 0.64 (0.12–3.36) | 6 (24) | 0.17 (0.03–0.78)# | 5 (20) | 0.51 (0.09–2.78) | 1 (4) | 0.59 (0.01–49.03) |
| Non-13-valent vaccine | 15 | 4 | 2 (13) | 1 (Ref) | 7 (47) | 1 (Ref) | 5 (33) | 1 (Ref) | 10 (67) | 1 (Ref) | 5 (33) | 1 (Ref) | 1 (7) | 1 (Ref) |
| 13-valent vaccine | 177 | 4 | 78 (44) | 5.14 (1.11–48.24)# | 53 (30) | 0.49 (0.17–1.43) | 28 (16) | 0.38 (0.11–1.53) | 39 (22) | 0.14 (0.04–0.49) | 40 (23) | 0.60 (0.18–2.38) | 3 (2) | 0.24 (0.02–13.57) |
| Non-13-valent vaccine | 15 | 4 | 2 (13) | 1 (Ref) | 7 (47) | 1 (Ref) | 5 (33) | 1 (Ref) | 10 (67) | 1 (Ref) | 5 (33) | 1 (Ref) | 1 (7) | 1 (Ref) |
| Total | 192 | 4 | 80 (42) | 60 (31) | 33 (17) | 49 (26) | 45 (24) | 4 (2) | ||||||
Bold indicates statistical significance. ICU: intensive care unit; Ref: reference. #: not significant after adjustment for multiple comparisons (Holm’s method).